BioArray Q&A: Roche NimbleGen CEO Gerd Maass on Taking a Tech Company into Personalized Healthcare
July 14, 2009
BioArray Q&A: Roche NimbleGen CEO Gerd Maass on Taking a Tech Company into Personalized Healthcare
Before taking over as CEO of Roche NimbleGen 13 months ago, Gerd Maass spent most of his professional life working in research and development for pharmaceutical and diagnostics companies. Now one of his main goals is steering the firm, which Roche paid $272.5 million to acquire in 2007, towards wider involvement in drug and test development.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Germany's ImaGenes, Partners to Use $4M Gov't Grant in Array-Based Nutrigenomics Study
July 14, 2009 / BioArray News - In Print
September 14, 2010 / BioArray News - Illumina to Submit Cytogenetics Package to FDA, Commits to Using Arrays in Dx
January 26, 2010 / BioArray News - Eli Lilly Taps SeqWright to Use Roche NimbleGen and 454 Tools in Psychiatric Diseases Study
August 4, 2009 / BioArray News - Team IDs Recurrent NOTCH1 Mutations in CLL Exomes
June 13, 2011 / GenomeWeb Daily News